Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research Note

Assessing the impact of coronavirus disease 2019 on mortality: a population-based, matched case-control study

Adi Turjeman 1,2, *, Eytan Wirtheim 3, Itamar Poran 2,4, Leonard Leibovici 1,2

1) Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel
2) Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3) Management, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel
4) Intensive Care Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel

OBJECTIVES: Estimating the isolated effect of coronavirus disease 2019 (COVID-19) on the risk of mortality is challenging. We aimed to determine whether COVID-19 was associated with high rates of mortality independently of age, sex and underlying disorders.

METHODS: A population-based, matched, case-control study of adults insured by Clalit Health Services was performed. Cases were defined as patients who died of all causes between July and December 2020. Each case was matched in a ratio of 1:1 with a living control based on age, sex and co-morbidities. An unconditional logistic regression analysis was performed to identify independent risk factors for mortality.

RESULTS: A total of 2874 patients who died were successfully matched with 2874 living controls. The prevalence of COVID-19 was higher among the patients who died than among the controls (13.5% [387/2874] vs. 4% [115/2874], respectively; OR, 3.73; 95% CI, 3.01-4.63; p < 0.001). A significantly increased odds of mortality was also observed in patients with COVID-19 without underlying diseases (OR, 3.67; 95% CI, 2.58-5.23) and in patients with COVID-19 and underlying diseases (OR, 3.77; 95% CI, 2.87-4.94). A multi-variate logistic analysis showed that COVID-19 (OR, 2.01; 95% CI, 1.07-3.77), low socio-economic status (OR, 1.36; 95% CI, 1.02-1.82), dementia (OR, 2.50; 95% CI, 2.10-3.01), smoking (OR, 1.35; 95% CI, 1.13-1.63) and an interaction variable of age >80 years and COVID-19 (OR, 2.27; 95% CI, 1.14-4.54) were independent risk factors for mortality, whereas influenza vaccination and high body mass index were associated with lower rates of mortality.

CONCLUSION: Testing positive for COVID-19 increased the risk of death three folds, regardless of underlying disorders. These results emphasize the effect of COVID-19 on mortality during the early period of the COVID-19 outbreak, when no vaccines or effective therapeutics were available. Adi Turjeman, Clin Microbiol Infect 2023;29:111.e1–111.e4

© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

INTRODUCTION

Since first detected in China, the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has spread rapidly around the globe. The first case of COVID-19 was confirmed in Israel on 21 February 2020. WHO declared the COVID-19 outbreak a global pandemic on March 2020 [1].

Patients of older age and with pre-existing health conditions are at an increased risk of severe COVID-19 [2–4]. In a systematic review and meta-analysis of 42 studies and 423 117 patients, a statistically significant effect of older age, male sex, and chronic co-morbidities on the fatal outcome of COVID-19 was found [4]. Given the fact that these risk factors also contribute to an increased risk of premature death, estimating the independent effect of COVID-19 on the risk of mortality is challenging. The association between COVID-19 and the risk of mortality among healthy and non-elderly people is controversial.

In this retrospective study, we aimed to determine whether COVID-19 was associated with high rates of mortality independently...
of age, sex and underlying disorders during the first wave of COVID-19 in Israel by comparing patients who died with their matched controls. In addition, we examined the interactions between COVID-19 and other risk factors for mortality. This case-control study was performed using the Clalit Health Services (CHS) database.

Methods

Setting and data source

A case-control study of patients insured by CHS was performed. CHS is the largest health-care delivery system in Israel, covering 53% of Israel’s population. The study population included all insured members from the Dan-Petah-Tikva and Tel Aviv districts who were aged ≥22 years as of 1 January 2020 and had continuous membership in Clalit for at least 5 years before inclusion.

Cases and controls

The cases were all people who died of all causes between 1 July 2020 and 31 December 2020. Each case was matched in a ratio of 1:1 with a living control based on age (±90 days), sex and underlying disorders during the first wave of COVID-19 with death were included in a multi-variate analysis using general-ized linear models. We used a logistic regression model (unconditional) to identify independent risk factors for mortality. The goodness of fit of the multi-variate logistic model was assessed using the Akaike information criterion. The associations between the risk factors and death are presented as ORs with their 95% CIs, calculated using the Wald method. Because the proportion of missing data was low (3.1%, 176/5748), no imputation method was used. The statistical analyses were performed using IBM SPSS Statistics, version 26.

Ethical considerations

This study was approved by the Rabin Medical Center Institutional Review Board. The requirement for informed consent was waived.

Results

A total of 603,526 individuals aged ≥22 years were continuous members of CHS for a period of at least 5 years before 2020, of whom 3048 died between 1 July 2020 and 31 December 2020. We managed to successfully match 2874 cases (94% of the total) with 2874 controls based on age, sex and underlying diseases.

The demographic and clinical characteristics of the cases and controls are presented in Table 1. The median age of the cohort was 85 (interquartile range, 74–90) years, and 47% (2702/5748) were women. A significantly higher proportion of the cases had dementia, were from a lower SES, had lower BMI, were less likely to receive influenza vaccination in 2019 and were more likely to be current smokers compared with their matched controls.

The rate of COVID-19 was significantly higher among the patients who died than among the control subjects (13.5% [387/2874] vs. 4.0% [115/2874] p < 0.001).

| Variable | Dead (cases) | Alive (controls) | p value |
|----------|--------------|-----------------|---------|
| Age, median (IQR), y | 85 (74–91) | 85 (74–90) | NA |
| Sex, malea | 1351 (47.0) | 1351 (47.0) | NA |
| Ethnicity | | | 0.34 |
| Jews | 2687 (98.0) | 2719 (98.4) | NA |
| Arabs | 54 (2.0) | 45 (1.6) | |
| Low socio-economic status | 130 (4.6) | 88 (3.1) | 0.004 |
| BMI, median (IQR) | 25.7 (22.7–29.7) | 27.1 (24.0–30.5) | <0.001 |
| Smoking status – current smoker | 331 (11.7) | 259 (9.1) | 0.001 |
| Neoplasmsb | | | NA |
| No | 2410 (83.9) | 2410 (83.9) | |
| Acute leukaemia | 1 (0.0) | 1 (0.0) | |
| Other neoplasms | 463 (16.1) | 463 (16.1) | |
| Kidney diseasesb | | | NA |
| No | 2443 (85.0) | 2442 (85.0) | |
| Chronic kidney disease | 403 (14.0) | 403 (14.0) | |
| Haemodialysis | 28 (1.0) | 28 (1.0) | |
| COPDb | 209 (7.3) | 209 (7.3) | |
| Ischaemic heart diseaseb | 437 (15.2) | 437 (15.2) | |
| Congestive heart failureb | 365 (12.7) | 365 (12.7) | |
| Diabetes mellitusb | 1261 (43.9) | 1261 (43.9) | |
| Cerebrovascular disease | 315 (11.0) | 286 (10.0) | 0.211 |
| Peripheral vascular disease | 72 (2.5) | 61 (2.1) | 0.335 |
| Dementia | 427 (14.9) | 193 (6.7) | <0.001 |
| Obesity | 148 (5.1) | 180 (6.3) | 0.069 |
| HIV | 8 (0.3) | 3 (0.1) | 0.131 |
| Influenza vaccination in 2019 | 1773 (61.7) | 1900 (66.1) | <0.001 |
| COVID-19 | 387 (13.5) | 115 (4.0) | <0.001 |

BMI, body mass index; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; HIV, human immuno-deficiency virus; IQR, inter-quartile range; NA, not applicable.

a Data are presented as number (%) unless otherwise indicated.

b Matching criteria.
vs. 4% (115/2874), respectively; \( p < 0.001 \) (Table 1). Among 387 patients with COVID-19 who died, 278 (72%) died within 30 days of a positive COVID-19 test result (Fig. 1). In a univariate analysis, a 3.73-fold increase in the odds of mortality was observed in the patients with COVID-19 (OR, 3.73; 95% CI, 3.01–4.63) (Table 2). Significantly increased odds of mortality were also observed in patients with COVID-19 without underlying diseases (OR, 3.67; 95% CI, 2.58–5.23) and in patients with COVID-19 and underlying diseases (OR, 3.77; 95% CI, 2.87–4.94) (Table 2).

The multi-variate analysis showed that COVID-19 (OR, 2.01; 95% CI, 1.07–3.77), low SES (OR, 1.36; 95% CI, 1.02–1.82), dementia (OR, 2.50; 95% CI, 2.10–3.01), current smoking (OR, 1.35; 95% CI, 1.13–1.63) and an interaction variable of age >80 years and COVID-19 (OR, 2.27; 95% CI, 1.14–4.54) were independent risk factors for mortality, whereas influenza vaccination in 2019 (OR, 0.80; 95% CI, 0.72–0.90) and higher BMI (OR per BMI increment of 1 kg/m\(^2\), 0.96; 95% CI, 0.95–0.97) were associated with lower rates of mortality (Table 3).

### Table 2
Association between coronavirus disease 2019 and mortality among patients with or without underlying disorders

| Population | Dead | Alive | OR (95% CI) |
|------------|------|-------|-------------|
| All patients with COVID-19 | 387/2874 | 115/2874 | 3.73 (3.01–4.63) |
| Patients with COVID-19 and underlying disorders | 245/1859 | 72/1859 | 3.77 |
| Patients with COVID-19 without underlying disorders | 142/1015 | 43/1015 | 3.67 |

COVID-19, coronavirus disease 2019.

### Discussion

In this case-control study, we found that COVID-19 is an independent risk factor for mortality after controlling for age, sex and co-morbidities which were considered as potential risk factors for mortality. The odds of death for individuals who tested positive for COVID-19 were increased by more than three folds. This was even more prominent among individuals aged >80 years. An increased risk of mortality was also observed among people without underlying diseases and with COVID-19. Dementia, smoking and low SES were also independently associated with higher mortality rates, whereas receiving influenza vaccination in 2019 and high BMI were found to have a protective effect.

Several studies have tried to assess both the direct and indirect effects of COVID-19 on mortality. There are difficulties in evaluating the direct effect of COVID-19 on mortality because other frequent co-morbidities may affect this association. In this study, we used a multivariate analysis for mortality. Multi-variate analysis using generalised linear models. Goodness of fit- Akaike information criteria 6681.623, \( N = 5572 \), constant = 1.001.

### Table 3
Multivariate analysis for mortality

| Risk factor | Multi-variate logistic regression analysis OR (95% CI) | \( p \) value |
|-------------|------------------------------------------------------|--------------|
| Age, y      |                                                      |              |
| <65         | Reference                                            |              |
| >65–80      | 1.04 (0.84–1.28)                                     | 0.75         |
| >80         | 0.95 (0.78–1.16)                                     | 0.61         |
| Low socio-economic status | 1.36 (1.02–1.82)                                   | 0.036        |
| BMI         | 0.96 (0.95–0.97)                                     | <0.001       |
| Dementia    | 2.50 (2.10 to –3.01)                                 | <0.001       |
| Influenza vaccine in 2019 | 0.80 (0.72–0.90)                               | <0.001       |
| Smoking status - current smoker | 1.35 (1.13–1.63)                             | 0.001        |
| COVID-19    | 2.01 (1.07–3.77)                                     | 0.029        |
| Interaction of age between 65 and 80 y and COVID-19 | 2.00 (0.94–4.25)                             | 0.073        |
| Interaction of age >80 y and COVID-19 | 2.27 (1.14–4.54)                               | 0.02        |

BMI, body mass index; COVID-19, coronavirus disease 2019.

\(^4\) Multi-variate analysis for mortality. Multi-variate analysis using generalised linear models. Goodness of fit- Akaike information criteria 6681.623, \( N = 5572 \), constant = 1.001.
matched case-control design, which allows us to eliminate potential confounding factors which may influence mortality (age, sex or co-morbidities).

Studies investigating the risk factors for COVID-19 severity and fatality were recently published [6]. Age is a well-known independent risk factor for increased morbidity and mortality [7]. We found that among patients with COVID-19, older age was the greatest risk factor for mortality. The plausible reasons for these results include age-related co-morbidities (not accounted for in the matching) and lower efficiency of the immune system [8].

Another known risk factor for mortality among patients with COVID-19 is dementia. Tahira et al. [9] found that all-cause dementia and Alzheimer disease were age-independent risk factors for COVID-19-related mortality. In our study, patients with dementia had a 2.5-fold increased risk of death.

Several studies have described a potential protective effect of influenza vaccination against COVID-19 [10,11]. In our study, we found that patients who received influenza vaccination in 2019 had lower mortality rates in 2020 than non-vaccinated patients. This can be explained by “well managed” or “healthy user” biases; patients who adhere to medical treatments or preventive therapies are more likely to have better health outcomes.

There are some conflicting results in the literature regarding the association between BMI and mortality. Although several studies have demonstrated that being overweight or overweight is associated with an increased risk of mortality [12–15], others have reported results similar to ours, i.e. being overweight is associated with a decreased risk of mortality [16,17]. Low SES has been associated with morbidity and premature mortality world-wide. In a large multi-cohort study with 1.7 million participants from the United States, Europe and Australia, low SES was associated with a 26% higher risk of mortality. The strongest association was found between current smoking and mortality [18]. In our study, both low SES and current smoking were independently associated with increased mortality.

Our study has limitations. The patients with COVID-19 were those who were infected with the wild-type virus. Our study provides an insight into the impact of COVID-19 on mortality at the beginning of the pandemic, when little was known about this novel virus and no vaccines were available. Residual confounding by other underlying disorders cannot be ruled out. We used OR as the measure of association between exposure and outcomes. However, if the outcome of interest is rare, OR is a good estimate of relative risk [19]. In our study, death occurred in 0.5% of the total population (3048/603 526).

In conclusion, we demonstrated that COVID-19 was independently associated with a 3.7-fold increased OR for mortality during the first wave of COVID-19 in Israel. People without underlying diseases and with COVID-19 were also at an increased risk of dying. The odds of dying were even higher in the older patient group (aged >80 years) with COVID-19. These results emphasize the effect of COVID-19 on mortality during the early period of the COVID-19 outbreak, when prevention efforts were focused on face masks, hand hygiene, social distancing and lock-down, and no vaccines or effective therapeutics were available.

Transparency declaration

The authors declare that they have no conflicts of interest.

Author contributions

All authors contributed to the study’s conception and design. A.T. and L.L.: material preparation, data collection and analysis; A.T. and L.L.: writing of the first draft of the manuscript; and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.08.016.

References

[1] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19.
[2] Treska-Schwarzbach M, Haas L, Reda S, Pilic A, Borodova A, Karimi K, et al. Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. BMC Med 2021;19: 1–26. https://doi.org/10.1186/s12916-021-02058-6.
[3] Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet Reg Health Eur 2021;6: 100109. https://doi.org/10.1016/j.lanepe.2021.100109.
[4] Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021; 21:1–28. https://doi.org/10.1186/s12879-021-06536-3.
[5] Goldberger N, Aburbeh M, Haklai Z. Leading causes of death in Israel, 2000–2018. Ministry of Health; 2021. https://www.health.gov.il/PublicationsFiles/CausesOfDeaths2018_Summary.pdf.
[6] Booth A, Reed AB, Ponzo S, Vassaea A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021; 16:e0247461. https://doi.org/10.1371/journal.pone.0247461.
[7] Levin AT, Hanage WP, Ouzzu-Boaitey N, Cochran KB, Walsh SP, Meyrowitz-Katz G. Assessing the specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol 2020;35:1123–38. https://doi.org/10.1007/s10654-020-00968-1.
[8] Mahase E. Covid-19: why are age and obesity risk factors for serious disease? BMJ 2020;371:n4130. https://doi.org/10.1136/bmj.n4130.
[9] Tahira AC, Verjovski-Almeida S, Ferreira ST. Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients. Alzheimers Dement 2021; 17:1818–31. https://doi.org/10.1016/j.dadm.2021.02.1252.
[10] Conlon A, Ashur C, Washer I, Eagle KA, Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control 2021;49:894–700. https://doi.org/10.1016/j.ajic.2021.02.012.
[11] Jehi L, Ji X, Milinovich A, Rubin BP, Gordon S, et al. Individualizing risk prediction for positive coronavirus disease 2019 testing: results from 11,672 patients. Chest 2020;158:1364–75. https://doi.org/10.1016/j.chest.2020.05.580.
[12] Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol 2018;6: 944–53. https://doi.org/10.1016/S2213-8587(18)30288-2.
[13] Aune D, Sen A, Prasad M, Norat T, Vassaea A, Thompson SG, et al. BMI and all-cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016;353:i2156. https://doi.org/10.1136/bmj.i2156.
[14] Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan LM, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211–9. https://doi.org/10.1056/NEJMoa1000367.
[15] Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Zwart P, et al. Body mass index and all-cause mortality: a population-based meta-analysis of 944 cohort studies with 6 million adults in the UK. Lancet Diabetes Endocrinol 2018;6: 944–53. https://doi.org/10.1016/S2213-8587(18)30288-2.
[16] Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016;353:i2156. https://doi.org/10.1136/bmj.i2156.
[17] Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan LM, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211–9. https://doi.org/10.1056/NEJMoa1000367.
[18] Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776–86. https://doi.org/10.1016/S0140-6736(16)30175-1.
[19] Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;399:71–82. https://doi.org/10.1001/jama.2012.113905.